On the sidelines of the inaugural annual global AlUla Conference for Emerging Market Economies in Al Ula, Saudi Arabia (February 16-17), Saudi Arabia's Finance Ministry and the International Monetary ...

The Ontario Securities Commission (OSC) announced today it will participate in a multi-jurisdictional settlement, along with other provincial and U.S. state securities regulators, with GS Partners and ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

and heads of other International Financial Institutions and the Arab Coordination Group. Following the meeting, Kristalina Georgieva, Managing Director of the IMF, and Mohammed Aljadaan, Finance ...

Arne Dedert / Picture Alliance / Getty Images Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates. Revenue and adjusted earnings ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of its HPV vaccine, Gardasil, to reach $11 billion by 2030. The result ...